Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
November 07 2023 - 10:00AM
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage
biotechnology company developing novel molecular glue degrader
(MGD)-based medicines, today announced the company will present
preclinical data at the American College of Rheumatology (ACR)
Convergence Annual Meeting held November 10-15 in San Diego, CA.
The data demonstrate that MRT-6160, a novel, highly selective MGD
targeting VAV1, attenuated disease progression in a murine
collagen-induced arthritis (CIA) model.
In vitro, MRT-6160 induced selective degradation
of VAV1, and attenuated TCR- and BCR-mediated activation and
function of primary human T- and B-cells. In the CIA model, oral
dosing of MRT-6160 elicited rapid VAV1 degradation across multiple
tissues in a dose-dependent manner. Over the course of 20 days,
MRT-6160 significantly decreased disease progression and endpoint
functional scores compared to vehicle and showed a trend towards
superior activity compared to an anti-TNF antibody.
“We are highly encouraged by these preclinical
data, which we believe further establish the importance of VAV1 as
a potential therapeutic target in T- and B-cell mediated
autoimmunity, as well as MRT-6160’s potential to broadly treat
autoimmune and inflammatory diseases including rheumatoid
arthritis, multiple sclerosis, inflammatory bowel disease,
psoriasis and other autoimmune diseases,” said Owen Wallace, Ph.D.,
Chief Scientific Officer of Monte Rosa Therapeutics. “Together with
extensive preclinical data in other models of autoimmunity, these
promising results further support MRT-6160 as it advances to the
clinic, and we look forward to our anticipated IND filing in the
first half of next year.”
Poster presentation
details:
Poster Presentation: A VAV1-Directed Molecular
Glue Degrader, MRT-6160, Reduces Joint Inflammation in the
Collagen-Induced Arthritis Autoimmune Disease Model (abstract
#0082)Session: Poster Session A: T Cell Biology
& Targets in Autoimmune & Inflammatory
DiseaseDate: Sunday, November 12, 2023
Time: 9:00-11:00 am PTPresenter:
Marisa Peluso, Director, Target and Discovery
BiologyLocation: Poster Hall
About VAV1 and MRT-6160VAV1, a
Rho-family guanine nucleotide exchange factor, is a key signaling
protein downstream of both the T-and B-cell receptors. VAV1
expression is restricted to blood and immune cells, including T and
B cells. Preclinical studies have shown that targeted degradation
of VAV1 protein via an MGD modulates both T- and B-cell
receptor-mediated activity. This modulation is evident both in
vitro and in vivo, demonstrated by a significant decrease in
cytokine secretion, proteins vital for maintaining autoimmune
diseases. Moreover, VAV1-directed MGDs have shown promising
activity in preclinical models of autoimmune diseases and thus have
the potential to provide therapeutic benefits in multiple
indications, such as multiple sclerosis, rheumatoid arthritis, and
dermatological disorders.
MRT-6160 is a potent, highly selective, and
orally bioavailable degrader of VAV1, which has shown deep
degradation of its target with no detectable effects on other
proteins. Preclinical studies demonstrate MRT-6160 inhibits disease
progression in in vivo autoimmunity models.About Monte
RosaMonte Rosa Therapeutics is a clinical-stage
biotechnology company developing highly selective molecular glue
degrader (MGD) medicines for patients living with serious diseases
in the areas of oncology, autoimmune and inflammatory diseases, and
more. MGDs are small molecule protein degraders that have the
potential to treat many diseases that other modalities, including
other degraders, cannot. Monta Rosa’s QuEEN™ (Quantitative and
Engineered Elimination of Neosubstrates) discovery engine combines
AI-guided chemistry, diverse chemical libraries, structural biology
and proteomics to identify degradable protein targets and
rationally design MGDs with unprecedented selectivity. The QuEEN
discovery engine enables access to a wide-ranging and
differentiated target space of well-validated biology across
multiple therapeutic areas. Monte Rosa has developed the industry’s
leading pipeline of MGDs, which spans oncology, autoimmune and
inflammatory disease and beyond, and has a strategic collaboration
with Roche to discover and develop MGDs against targets in cancer
and neurological diseases previously considered impossible to
drug. For more information, visit www.monterosatx.com
Forward-Looking StatementsThis
communication includes express and implied “forward-looking
statements,” including forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include all statements that are not
historical facts, and in some cases, can be identified by terms
such as “may,” “might,” “will,” “could,” “would,” “should,”
“expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “continue,” “ongoing,” or the
negative of these terms, or other comparable terminology intended
to identify statements about the future. Forward-looking statements
contained in herein include, but are not limited to, statements
about our product development activities, including our
expectations around the potential of molecular glue degraders, the
potential of our pipeline of molecular glue degraders, including
our molecular glue degrader for VAV1, known as MRT-6160, , our
expectation of the relevance of our pre-clinical data for VAV1
and/or MRT-6160 and the potential relevance of such with respect to
potential therapeutic utility in immunological and/or inflammatory
disorders, our expectations regarding the advancement and timing of
ongoing pre-clinical and clinical development of MRT-6160,
including our estimated timing for filing of an investigational new
drug application therefor, our ability to initiate clinical studies
for MRT-6160, our expectations regarding potential therapeutic
opportunities for VAV1 as a target and specifically for MRT-6160,
our expectations regarding medical needs and potential therapeutic
opportunities for MRT-6160. By their nature, these statements are
subject to numerous risks and uncertainties, including those risks
and uncertainties set forth in our most recent Annual Report on
Form 10-K for the year ended December 31, 2022, filed with the U.S.
Securities and Exchange Commission on March 16, 2023, and any
subsequent filings, that could cause actual results, performance or
achievement to differ materially and adversely from those
anticipated or implied in the statements. You should not rely upon
forward-looking statements as predictions of future events.
Although our management believes that the expectations reflected in
our statements are reasonable, we cannot guarantee that the future
results, performance, or events and circumstances described in the
forward-looking statements will be achieved or occur. Recipients
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date such statements are
made and should not be construed as statements of fact. We
undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, any future
presentations, or otherwise, except as required by applicable
law.
Investors Andrew Funderburk, Kendall
IRir@monterosatx.com
Media Cory Tromblee, Scient
PRmedia@monterosatx.com
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
From Apr 2024 to May 2024
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
From May 2023 to May 2024